CD4 and sarcoidosis: Thus, although medications that inhibit pathogenic CD4+ T-cells show some clinical benefit in sarcoidosis, a recent review suggested that the goal of future treatments should be to ultimately restore T-cell function since re-invigorated T-cell function corresponded with clinical resolution [20,92].